The Gores Group Exits with $1.325 Billion

by | Aug 17, 2015 4:11 pm | Biotechnology, Private Equity | 0 comments

Last week’s Biggest Deal was Mallinckrodt plc’s (NYSE: MNK) $1.325 billion acquisition of Therakos, Inc., an immunotherapy company, from The Gores Group. Gores acquired Therakos back in October 2012 for an undisclosed price from Ortho-Clinical Diagnostics. The transaction is expected to be accretive by no less than $0.10 per share to Mallinckrodt’s adjusted diluted fiscal 2016 earnings and increasingly accretive thereafter. With roughly 60% of Therakos’ revenue in the U.S., it expects fiscal 2015 net sales of $185 to $195 million, and anticipates high single-digit growth off that base going forward. Read More »